{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:11Z","timestamp":1791216731104,"version":"4.1.0"},"reference-count":46,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"DOI":"10.1210\/en.2003-1271","type":"journal-article","created":{"date-parts":[[2003,12,9]],"date-time":"2003-12-09T01:15:13Z","timestamp":1070932513000},"page":"1527-1538","source":"Crossref","is-referenced-by-count":48,"title":["Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor \u03b3"],"prefix":"10.1210","volume":"145","author":[{"given":"Maura","family":"Agostini","sequence":"first","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Savage","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"},{"name":"Department of Clinical Biochemistry (D.B.S., S.O.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Wood","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron G.","family":"Smith","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Rajanayagam","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Garnes","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline (K.T.G., S.H.L.), Isotope Chemistry, Upper Merion, Pennsylvania 19406"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney H.","family":"Levinson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline (K.T.G., S.H.L.), Isotope Chemistry, Upper Merion, Pennsylvania 19406"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Eric","family":"Xu","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline (H.E.X., T.M.W.), Nuclear Receptor Discovery Research, Research Triangle Park, North Carolina 27709"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W. R.","family":"Schwabe","sequence":"additional","affiliation":[{"name":"Medical Research Council Laboratory of Molecular Biology (J.W.R.S.), Addenbrooke\u2019s Hospital, Cambridge CB2 2QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Willson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline (H.E.X., T.M.W.), Nuclear Receptor Discovery Research, Research Triangle Park, North Carolina 27709"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O\u2019Rahilly","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"},{"name":"Department of Clinical Biochemistry (D.B.S., S.O.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Krishna","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Departments of Medicine (M.A., M.G., D.B.S., E.M.W., A.G.S., O.R., S.O., K.C.), University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041202082648200_R1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1101\/gad.8.10.1224","article-title":"mPPAR\u03b32: tissue-specific regulator of an adipocyte enhancer.","volume":"8","author":"Tontonoz","year":"1994","journal-title":"Genes Dev"},{"key":"2019041202082648200_R2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR\u03b32, a lipid-activated transcription factor.","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"2019041202082648200_R3","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors \u03b1 and \u03b3.","volume":"94","author":"Kliewer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041202082648200_R4","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism.","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"2019041202082648200_R5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/22572","article-title":"Interleukin-4-dependent production of PPAR-\u03b3 ligands in macrophages by 12\/15-lipoxygenase.","volume":"400","author":"Huang","year":"1999","journal-title":"Nature"},{"key":"2019041202082648200_R6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0092-8674(00)81574-3","article-title":"Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR\u03b3.","volume":"93","author":"Nagy","year":"1998","journal-title":"Cell"},{"key":"2019041202082648200_R7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"15-Deoxy-\u0394 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR\u03b3.","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"2019041202082648200_R8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(95)90194-9","article-title":"A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor \u03b3 and promotes adipocyte differentiation.","volume":"83","author":"Kliewer","year":"1995","journal-title":"Cell"},{"key":"2019041202082648200_R9","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3).","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"2019041202082648200_R10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant-negative mutations in human PPAR\u03b3 are associated with severe insulin resistance, diabetes mellitus and hypertension.","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"2019041202082648200_R11","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","article-title":"Clinical and pathophysiological features of a metabolic syndrome resulting from mutations in the nuclear receptor PPAR\u03b3.","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"key":"2019041202082648200_R12","first-page":"408","article-title":"A novel heterozygous mutation in peroxisome proliferator-activated receptor-\u03b3 gene in a patient with familial partial lipodystrophy.","volume":"87","author":"Agarwal","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041202082648200_R13","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.2337\/diabetes.51.12.3586","article-title":"PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.","volume":"51","author":"Hegele","year":"2002","journal-title":"Diabetes"},{"key":"2019041202082648200_R14","first-page":"348","article-title":"The syndromes of resistance to thyroid hormone.","volume":"14","author":"Refetoff","year":"1993","journal-title":"Endocr Rev"},{"key":"2019041202082648200_R15","first-page":"1262","article-title":"Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone \u03b2 receptors in thyroid hormone resistance syndrome.","volume":"8","author":"Collingwood","year":"1994","journal-title":"Mol Endocrinol"},{"key":"2019041202082648200_R16","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1210\/jcem.80.11.7593433","article-title":"Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone \u03b2 receptors?","volume":"80","author":"Hayashi","year":"1995","journal-title":"J Clin Endocrinal Metab"},{"key":"2019041202082648200_R17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/bmj.321.7256.252","article-title":"Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.","volume":"321","author":"Krentz","year":"2000","journal-title":"BMJ"},{"key":"2019041202082648200_R18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/diabetes.48.7.1415","article-title":"A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-\u03b3 reverses the diabetic phenotype of the Zucker diabetic fatty rat.","volume":"48","author":"Brown","year":"1999","journal-title":"Diabetes"},{"key":"2019041202082648200_R19","author":"Fiedorek","year":"2000"},{"key":"2019041202082648200_R20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nsb892","article-title":"A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease.","volume":"10","author":"Kallenberger","year":"2003","journal-title":"Nat Struct Biol"},{"key":"2019041202082648200_R21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/415813a","article-title":"Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR\u03b1.","volume":"415","author":"Xu","year":"2002","journal-title":"Nature"},{"key":"2019041202082648200_R22","doi-asserted-by":"crossref","first-page":"31157","DOI":"10.1016\/S0021-9258(18)47403-0","article-title":"Functional analysis of a transactivation domain in the thyroid hormone \u03b2 receptor.","volume":"269","author":"Tone","year":"1994","journal-title":"J Biol Chem"},{"key":"2019041202082648200_R23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/377454a0","article-title":"A transcriptional corepressor that interacts with nuclear hormone receptors.","volume":"377","author":"Chen","year":"1995","journal-title":"Nature"},{"key":"2019041202082648200_R24","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1101\/gad.13.24.3209","article-title":"Mechanism of co-repressor binding and release from nuclear hormone receptors.","volume":"13","author":"Nagy","year":"1999","journal-title":"Genes Dev"},{"key":"2019041202082648200_R25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1099-1344(199908)42:8<797::AID-JLCR240>3.0.CO;2-O","article-title":"Direct tritium labeling of multifunctional compounds using organoiridium catalysis","volume":"42","author":"Shu","year":"1999","journal-title":"J Labelled Comp Radiopharm"},{"key":"2019041202082648200_R26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1172\/JCI117362","article-title":"Genetic analysis of twenty-nine kindreds with generalised and pituitary resistance to thyroid hormone.","volume":"94","author":"Adams","year":"1994","journal-title":"J Clin Invest"},{"key":"2019041202082648200_R27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/diabetes.50.10.2199","article-title":"Resistin\/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-\u03b3 action in humans.","volume":"50","author":"Savage","year":"2001","journal-title":"Diabetes"},{"key":"2019041202082648200_R28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1101\/gad.11.7.835","article-title":"Stoichiometric and steric principles governing repression by nuclear hormone receptors.","volume":"11","author":"Zamir","year":"1997","journal-title":"Genes Dev"},{"key":"2019041202082648200_R29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/377397a0","article-title":"Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor.","volume":"377","author":"Horlein","year":"1995","journal-title":"Nature"},{"key":"2019041202082648200_R30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/47069","article-title":"The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.","volume":"402","author":"Hu","year":"1999","journal-title":"Nature"},{"key":"2019041202082648200_R31","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1101\/gad.13.24.3198","article-title":"Molecular determinants of nuclear receptor-corepressor interaction.","volume":"13","author":"Perissi","year":"1999","journal-title":"Genes Dev"},{"key":"2019041202082648200_R32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1210\/mend.11.4.9914","article-title":"Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.","volume":"11","author":"Yoh","year":"1997","journal-title":"Mol Endocrinol"},{"key":"2019041202082648200_R33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/bbrc.1999.1071","article-title":"PPAR\u03b3 activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes.","volume":"261","author":"Pelton","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"2019041202082648200_R34","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N-(2-Benzoylphenyl)-l-tyrosine PPAR\u03b3 agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.","volume":"41","author":"Henke","year":"1998","journal-title":"J Med Chem"},{"key":"2019041202082648200_R35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1097-2765(00)80448-7","article-title":"Asymmetry in the PPAR\u03b3\/RXR\u03b1 crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.","volume":"5","author":"Gampe","year":"2000","journal-title":"Mol Cell"},{"key":"2019041202082648200_R36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-\u03b3.","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"2019041202082648200_R37","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1074\/jbc.275.8.5754","article-title":"A dominant negative peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) mutant is a constitutive repressor and inhibits PPAR\u03b3-mediated adipogenesis.","volume":"275","author":"Gurnell","year":"2000","journal-title":"J Biol Chem"},{"key":"2019041202082648200_R38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00125-003-1037-4","article-title":"A dominant negative PPAR\u03b3 mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3\u2013L1 cells.","volume":"46","author":"Park","year":"2003","journal-title":"Diabetologia"},{"key":"2019041202082648200_R39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/35895","article-title":"Role of the histone deacetylase complex in acute promyelocytic leukaemia.","volume":"391","author":"Lin","year":"1998","journal-title":"Nature"},{"key":"2019041202082648200_R40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/339593a0","article-title":"Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist.","volume":"339","author":"Damm","year":"1989","journal-title":"Nature"},{"key":"2019041202082648200_R41","first-page":"609","article-title":"A novel TR\u03b2 mutation (R383H) in resistance to thyroid hormone predominantly impairs corepressor release and negative transcriptional regulation.","volume":"12","author":"Clifton-Bligh","year":"1998","journal-title":"Mol Endocrinol"},{"key":"2019041202082648200_R42","doi-asserted-by":"crossref","first-page":"30175","DOI":"10.1074\/jbc.273.46.30175","article-title":"Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.","volume":"273","author":"Safer","year":"1998","journal-title":"J Biol Chem"},{"key":"2019041202082648200_R43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/35901","article-title":"Fusion proteins of the retinoic acid receptor-\u03b1 recruit histone deacetylase in promyelocytic leukaemia.","volume":"391","author":"Grignani","year":"1998","journal-title":"Nature"},{"key":"2019041202082648200_R44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng0298-126","article-title":"Distinct interactions of PML-RAR\u03b1 and PLZF-RAR\u03b1 with co-repressors determine differential responses to RA in APL.","volume":"18","author":"He","year":"1998","journal-title":"Nat Genet"},{"key":"2019041202082648200_R45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1358\/dof.2001.026.04.617323","article-title":"Farglitazar. Antidiabetic PPAR\u03b3 agonist.","volume":"26","author":"Sorbera","year":"2001","journal-title":"Drugs of the Future"},{"key":"2019041202082648200_R46","first-page":"772","article-title":"Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.","volume":"28","author":"Cox","year":"2000","journal-title":"Drug Metab Dispos"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/145\/4\/1527\/10786664\/endo1527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T12:14:48Z","timestamp":1623586488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/145\/4\/1527\/2878018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2003-1271","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}